Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion type Assertion NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_head.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion evidence source_evidence_literature NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion SIO_000772 21908430 NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion wasDerivedFrom befree-2016 NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion wasGeneratedBy ECO_0000203 NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.